医院模板
  • HOME
  • | /
  • ABOUT
    • Overview
    • Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
    • Collaborators
  • | /
  • R&D
    • TNP-2092 IV
    • TNP-2092 PO
    • TNP-2198 PO
    • TNP-2092 Topical
    • CRAB
    • NTM
  • | /
  • NEWS
    • Company News
    • Publications
    • Industry News
  • | /
  • JOIN US
    • Activities
    • Job Openings
  • | /
  • CONTACT
  • 中文
  • EN

TenNor presented Phase II results of TNP-2092 at 2020 CBIIC

2020-09-28 09:20

20200927.jpg


September 27, 2020/Suzhou --- TenNor Therapeutics presented Phase II results of TNP-2092 at 2020 China Biomed Innovation and Investment Conference.



download attachment(1)：
  • CBIIC 2020 丹诺医药 马振坤.pdf
share
WeChat
Sina Weibo
Facebook
Twitter
LinkedIn
Company News
Prev TenNor Initiated TNP-2198 Phase 1b/IIa Clinical Trials
Next WHO publishes list of bacteria for which new antibiotics are urgently needed

ABOUT

Overview

Team

Board of Directors

Scientific Advisory Board

Investors

Collaborators

R&D

TNP-2092 IV

TNP-2092 PO

TNP-2198 PO

TNP-2092 Topical

CRAB

NTM


NEWS

Company News

Publications

Industry News

JOIN US

Activities

Job Openings

 

CONTACT


©2013 TENNOR THERAPEUTICS LTD

电话咨询：020-000000
QQ咨询：258506508
微信客服
扫码咨询